Amgen reports Tezspire trial results. Amgen stock costs EUR 387.80 before November 3 results

Published on 10/21/2026 at 11:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Tezspire reached 64.8 percent remission at week 24 on October 20, 2026. Amgen stock costs EUR 387.80 on October 21, 2026 before November 3 results.

Pipeline and earnings calendar

Tezspire achieved 64.8 percent histologic remission at week 24 on October 20, 2026.
Amgen reported USD 10.05 billion in Q2 2026 revenue, up 9.5 percent year over year.
Amgen stock trades at EUR 387.80 at 11:08 a.m. CEST at Lang & Schwarz on October 21, 2026.

Isometrische 3D-Illustration einer biopharmazeutischen Wertschöpfungskette von Labor bis Vertrieb mit Bioreaktoren — Amgen Inc. (ISIN US0311621009) dargestellt als isometrisches 3D-Diagramm der biopharmazeutischen Wertschöpfungskette von Labor bis Versand, Illustration mit AI erstellt.

Amgen (ISIN US0311621009) reported positive Phase 3 results for Tezspire in eosinophilic esophagitis on October 20, 2026, while the stock was trading at EUR 387.80 at Lang & Schwarz on October 21, 2026 at 11:08 a.m. CEST. The result gives investors a fresh pipeline signal before Amgen's next scheduled earnings report.

Tezspire delivers a measurable trial result

According to Amgen, histologic remission at week 24 reached 64.8 percent for the 210 mg dose and 68.9 percent for the 420 mg dose, compared with 3.5 percent for placebo. The trial evaluated 368 patients who received treatment every four weeks.

The clinical result is relevant because the higher-dose remission rate exceeded placebo by 65.4 percentage points at week 24. At week 52, remission stood at 67.8 percent for the 210 mg dose and 63.3 percent for the 420 mg dose, versus 5.4 percent for placebo.

What does the earnings setup show?

Amgen's latest reported quarter also supplied a quantified counterpoint. MarketBeat reported that Q2 2026 revenue reached USD 10.05 billion, up 9.5 percent from the prior year, while earnings per share came to USD 6.29 versus USD 5.62 consensus. That beat of USD 0.67 gives the pipeline news a stronger financial backdrop.

Three dates define the recent sequence

On August 4, 2026, Amgen reported Q2 2026 revenue of USD 10.05 billion. On September 22, 2026, the company announced positive Phase 3 topline results for dazodalibep in Sjogren's disease, as listed on its Amgen investor-relations page. On October 20, 2026, Amgen published the full Tezspire CROSSING results with 64.8 percent remission at week 24.

November 3 is the next key date

MarketBeat lists November 3, 2026, after the market close, as Amgen's next Q3 2026 earnings date. Its estimate calls for USD 5.77 earnings per share and USD 10.06 billion in revenue, compared with USD 5.64 and USD 9.56 billion in the prior-year quarter.

Stock price and valuation context

Amgen's primary listing is Nasdaq, where the October 20, 2026 close was USD 438.94. The 52-week range was USD 288.00 to USD 447.03, and market capitalization was USD 237.3 billion. The euro quotation puts the stock in the same broad valuation conversation, but the two currencies should not be combined in one performance calculation.

Amgen stock was trading at EUR 387.80 at Lang & Schwarz on October 21, 2026 at 11:08 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Amgen stock.